Cosette Pharmaceuticals Acquires Vyleesi from Palatin Technologies
January 3, 2024
Cosette Pharmaceuticals, a U.S. specialty pharmaceutical company backed by Avista Healthcare Partners, has acquired the Vyleesi (bremelanotide) product and related intellectual property from Palatin Technologies. The deal transfers five Orange Book-listed patents (protection through 2041) and aims to expand Cosette’s women's health portfolio while ensuring continued patient access during the transition.
- Buyers
- Cosette Pharmaceuticals, Inc., Avista Healthcare Partners
- Targets
- Vyleesi (bremelanotide injection)
- Sellers
- Palatin Technologies, Inc.
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Related Acquisitions
-
Hamilton Lane Acquires Significant Equity Interest in Cosette Pharmaceuticals; Partners with Avista Capital
July 17, 2024
Pharmaceuticals
Funds managed by Hamilton Lane have acquired a significant equity interest in Cosette Pharmaceuticals from Avista Capital Partners and its co-investors. Avista and Hamilton Lane will jointly control Cosette as the company strengthens its balance sheet to accelerate R&D, product innovation and future M&A activity.
-
Incyte Acquires Villaris Therapeutics and Auremolimab (VM6)
October 3, 2022
Biotechnology
Incyte has entered into an agreement to acquire Villaris Therapeutics, obtaining exclusive global rights to auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody targeting vitiligo and other autoimmune diseases. Villaris shareholders will receive $70 million upfront and may receive up to $1.36 billion in development and commercial milestone payments; the acquisition expands Incyte's inflammation/autoimmunity and dermatology portfolio.
-
Cosette Pharmaceuticals Acquires Global Rights to Intrarosa from Endoceutics
June 8, 2023
Pharmaceuticals
Cosette Pharmaceuticals has acquired the global commercial rights to Intrarosa from Endoceutics, Inc., including issued and pending patents protecting the product. The acquisition strengthens Cosette's women's health portfolio and expands its global footprint through existing distribution partners and planned Asian launches in 2025.
-
AbbVie Acquires Syndesi Therapeutics
March 1, 2022
Biotechnology
AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.
-
Juvisé Pharmaceuticals Acquires Ponvory (ex-US/Canada) from Actelion; Bpifrance and Pemberton Invest in Juvisé
March 26, 2024
Pharmaceuticals
Juvisé Pharmaceuticals has acquired global commercial rights (excluding the United States and Canada) to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd., a Johnson & Johnson company. To fund the transaction, French sovereign fund Bpifrance and private credit manager Pemberton Asset Management took minority stakes in Juvisé; Juvisé will commercialize and assume manufacturing duties for Ponvory in Europe.
-
Eli Lilly Acquires Verve Therapeutics
July 25, 2025
Biotechnology
Eli Lilly and Company completed the acquisition of Verve Therapeutics, a Boston-based clinical-stage developer of one-time gene-editing therapies for cardiovascular disease. Lilly said the deal will integrate Verve's genetic-medicine programs into its cardiometabolic research to advance potential lifelong cardiovascular risk–reduction treatments.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.